A Janus kinase inhibitor was approved for the treatment of active polyarticular course juvenile idiopathic arthritis among patients aged 2 years or older.
The US Food and Drug Administration has approved tofacitinib for the treatment of active polyarticular course juvenile idiopathic arthritis among pediatric patients aged 2 years or older.
The FDA have identified several ingredients that may be connected to the recent reports of individuals with severe respiratory illness in connection with use of electronic smoking products.
In response to the release of a CDC report detailing increases in the use of e-cigarettes among youth in the US between 2011 and 2018, the FDA has released a statement detailing new limitations to the sale...
In 2010, the FDA mandated that 4 companies marketing long-acting β2 agonists perform trials comparing the safety of combination therapy with LABA plus an inhaled glucocorticoid vs an inhaled glucocorticoid...
